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Although the test systems should continu-
ously be evaluated and improved, we have to-
day a battery of tests which must be con-
sidered sufficiently reliable for a practical
screening of the mutagenicity of chemicals.
It may be emphasized that these genetic
tests are at least as reliable as other tests
used in toxicology; as a matter of fact, they
give information of the molecular mechanism
of the effects rarely encountered in other
toxicological test systems.
The mutagenicity tests, however, are re-
liable only as long as they are performed and
evaluated correctly. The present meeting
has clearly demonstrated that the mutageni-
city tests are by no means free from com-
plications; they can in fact hardly be per-
formed in a proper way without a great
deal of knowledge and experience.
Today we are to a great extent still dis-
cussing experiments with model substances
but we will soon reach the stage when this
experience has to be put into a large-scale
practice for the actual evaluation of chem-
icals that we are exposed to in the environ-
ment. This leads to the important question-
who is going to perform the tests?
The necessity of considering mutagenic
hazards of chemicals is rapidly being re-
cognized by industries and many industries
do a good job in their testing for mutageni-
city effects. There are, however, also many
cases, when the testing is done by people with
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poor or no previous training and without suf-
ficient understanding of the genetic problems
involved.
The practical aspects of mutagenicity
testing therefore does not only concern act-
ual testing procedures. A question of almost
equivalent importance is the training of gene-
ticists for this work.
There are all reasons to believe that the
need for competent scientists in this area
will increase rapidly in the future. This need
may in fact be further enhanced by the pos-
sibility of using mutagenicity tests also for
at least a preliminary screening of carcino-
genic actions of chemicals, as has been dis-
cussed during this meeting as well as at
many previous occasions. It therefore is nec-
essary to emphasize the responsibility of
governmental authorities both in this and in
other countries considering such a training
program.
The organization of the routine mutageni-
city testing probably will be solved in differ-
ent ways in different countries. It can be
assumed, however, that a great deal of this
testing activity will be based on contracts
with various laboratories, as it is generally
done in the United States. A major point
here is that some control be exerted that
these laboratories fulfill a required standard.
It is evident that such a control would be
greatly simplified if this testing activity is
centralized to highly specialized laboratories
performing mutagenicity tests for all or
large groups of industries in a country. In
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of such a laboratory, the responsibility for
which would be shared by the government
and industry. Another suggestion, along
somewhat similar lines, has recently been
brought up by the Swedish insurance com-
panies. They have pointed to the possibility
of arranging insurance policies with indust-
ries so the responsibility for mutagenic and
carcinogenic hazards of chemical products
is taken over by the insurance companies,
which would set up specialized testing la-
boratories for this purpose. One advantage of
such a solution might also be that different
organizations are responsible for the produc-
tion and for the testing of chemical products.
Discussion
Dr. E. Freese (NINDS): I want to thank Dr.
Ramel for making his excellent case for training,
and training grants. I want to say that the Environ-
mental Mutagen Society sponsors such a training
course under the direction of Dr. Legator. Unfor-
tunately it still has not obtained the money. I think
it should be clear that such training is much less
expensive than badly performed contracts. There's
unfortunately some silly regulations which prevent
the money from being spent for training and we
somehow should push to have these regulations
overcome.
Dr. E. B. Lewis (California Institute of Technol-
ogy): Dr. Ramel's comments reminded me that I
had not referred to a nice summary on the drug-
induced cancer problem by Frawmeige and Miller of
the NCI, who have in a letter to the editor summar-
ized all the literature on the important inductions
of tumors with chemicals. In connection with what
Dr. Ramel said about insurance companies, Fraw-
meige and Miller state that methods to link drug
prescriptions with subsequent diagnoses of disease
have been instituted as surveillance systems with
drug toxicity at the Kaiser Permanente in San
Francisco.
Dr. S. Abrahamson (Univ. of Wisconsin): I
think you need two levels of support: one for train-
ing of personnel and one for long-term support for
devising and continuing to devise the systems that
you want to see developed. I don't think they can
necessarily be tied to such agencies as contractual
ones. They have to be supported at different levels
and provide that kind of support over a long period
of time so that you're not in danger of tooling up a
team of technicians to develop systems and find out,
six months later, that you've been wiped out, by the
whim of some agency.
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